Piper sees six ‘quality’ Med Tech names whose stocks haven’t rallied

Medical Technology stocks have rebounded quickly in Q1 following a challenging Q4 of 2018 as the combination of solid year-end results and compelling outlooks for next year have led investors back into the names, Piper Jaffray analyst Matt O’Brien tells investors in a research note. The analyst, however, has identified six “quality” names that have not participated in the Q1 share appreciation, “despite consistently delivering beat-and-raises.” The basket of stocks include Abiomed (ABMD), Merit Medical (MMSI), AtriCure (ATRC), Neuronetics (STIM), SeaSpine (SPNE) and Nuvectra (NVTR).
https://thefly.com/landingPageNews.php?id=2883453